Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype Guided vs Conventional P2Y12 Blocker Selection in ACS
NCT01994941Phase 4Completed
- Sponsor
- The University of Hong Kong
- Start
- Aug 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by The University of Hong Kong. Primary endpoints: Platelet reactivity at 24 hours and Platelet reactivity at 1 month. Started Aug 2013; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01994941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994941.